A randomised phase III study on the effect of the chimeric anti-CD20 monoclonal antibody (Mabthera) [rituximab] during sequential chemotherapy followed by autologous stem cell transplantation in patients with relapse B-cell non-Hodgkin lymphoma (HOVON 44 study)

Trial Profile

A randomised phase III study on the effect of the chimeric anti-CD20 monoclonal antibody (Mabthera) [rituximab] during sequential chemotherapy followed by autologous stem cell transplantation in patients with relapse B-cell non-Hodgkin lymphoma (HOVON 44 study)

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Rituximab (Primary) ; Carmustine; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Filgrastim; Ifosfamide; Melphalan; Methotrexate
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2013 Planned number of patients changed from 300 to 340 as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Additional lead trial centres and investigators identified as reported by Netherlands Trial Register record.
    • 20 Oct 2009 Planned number of patients changed from 296 to 300 as reported by Netherlands Trial Register record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top